Ursodeoxycholic Acid Does Not Improve COVID-19 Outcome in Hospitalized Patients
2023
Francesca Colapietro | Giovanni Angelotti | Chiara Masetti | Dana Shiffer | Nicola Pugliese | Stella De Nicola | Francesco Carella | Antonio Desai | Monica Ormas | Marta Calatroni | Paolo Omodei | Michele Ciccarelli | Stefano Aliberti | Francesco Reggiani | Michele Bartoletti | Maurizio Cecconi | Ana Lleo | Alessio Aghemo | Antonio Voza
Ursodeoxycholic acid (UDCA) was demonstrated to reduce susceptibility to SARS-CoV-2 infection in vitro and improve infection course in chronic liver diseases. However, real-life evidence is lacking. We analyzed the impact of UDCA on COVID-19 outcomes in patients hospitalized in a tertiary center. Between January 2020 and January 2023, among 3847 patients consecutively hospitalized for COVID19, 57 (=UDCA group) were taking UDCA. The UDCA and the control groups (<i>n</i> = 3790) did not differ concerning comorbidities including diabetes mellitus type 2 (15.8% vs. 12.8%) and neoplasia (12.3% vs. 9.4%). Liver diseases and vaccination rate were more common in the UDCA group (14.0% vs. 2.5% and 54.4% vs. 30.2%, respectively). Overall mortality and CPAP treatment were 22.8 % and 15.7% in the UDCA, and 21.3% and 25.9% in the control group. Mortality was similar (<i>p</i> = 0.243), whereas UDCA was associated with a lower rate of CPAP treatment (OR = 0.76, <i>p</i> < 0.05). Treatment with UDCA was not an independent predictor of survival in patients hospitalized for COVID-19.
显示更多 [+] 显示较少 [-]